Pre-clinical development of SPY-DYS45-55, a CRISPR/Cas9 platform for Duchenne muscular dystrophy
SPY-DYS45-55(一种治疗杜氏肌营养不良症的 CRISPR/Cas9 平台)的临床前开发
基本信息
- 批准号:10001742
- 负责人:
- 金额:$ 49.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-01 至 2022-11-30
- 项目状态:已结题
- 来源:
- 关键词:AdultAdvanced DevelopmentAllelesBLT miceBecker Muscular DystrophyCRISPR therapeuticsCRISPR/Cas technologyCapsidCessation of lifeChildClinicalClinical DataCodeDNA Sequence AlterationDataDependovirusDiseaseDoseDuchenne muscular dystrophyDystrophinEligibility DeterminationExonsExposure toFoundationsFrequenciesGene DeliveryGenesGoalsGuide RNAHeartHumanImmune responseImmunityImmunosuppressionIndividualInjectionsIntronsKnowledgeLeadLongitudinal StudiesMendelian disorderMusMuscleMuscular AtrophyMutateMutationMyopathyPatientsPhasePhenotypeProceduresProductionProteinsReading FramesRecombinantsRegimenResearchSafetySerotypingSkeletal MuscleSpecificityTestingTherapeuticToxic effectTranslatingTreatment EfficacyTropismVirusWasting SyndromeWestern Blottingbaseboyscohortdesigngene therapygenome sequencinghumanized mouseimmunogenicityimmunoregulationimprovedimproved functioningin vivomouse modelmutantnoveloff-target mutationpre-clinicalpreclinical developmentpreclinical safetypreclinical toxicityprematurepromotervectorwhole genome
项目摘要
MyoGene Bio is a startup dedicated to developing cutting edge genetic therapies for muscle
diseases. In this proposal, the company will advance development of our potential therapeutic,
SPY-DYS45-55, a CRISPR/Cas9 gene editing platform for Duchenne muscular dystrophy (DMD)
in conjunction with research partners at UCLA. Duchenne is a devastating muscle wasting
disorder with no cure that is caused by out-of-frame mutations in the DMD gene. SPY-DYS45-55
removes a mutational hotspot in DMD to restore the reading frame for half of all Duchenne
patients by generating an in-frame exon 45-55 deletion. This deletion is associated with a very
mild phenotype in human Becker muscular dystrophy patients. Systemic delivery of gene editing
platforms to muscle represents a significant challenge. Certain serotypes of recombinant adenoassociated
virus (AAV) have tropism to skeletal muscle and heart. However, the immune
response to the virus prohibits repeated administration of AAV. Furthermore, pre-existing
immunity in some individuals (anticipated to be present in up to 70% of adults), precludes their
eligibility to take advantage of this treatment. The goal of this Fast Track proposal is to devise
strategies to overcome these challenges. In Phase I, we will determine an optimal
immunosuppression regimen that allows redosing of AAV in order to improve the efficacy and
applicability of SPY-DYS45-55. In Phase II, we will assess the long-term functional benefit,
toxicity, and off-target activity from single or multiple injections of AAV-SPY-DYS45-55 in our novel
mouse model containing a mutated human DMD gene. Ultimately, these studies will generate
the initial pre-clinical data needed to translate SPY-DYS45-55 to patients with Duchenne muscular
dystrophy.
MyoGene Bio是一家致力于开发尖端肌肉基因疗法的初创公司
疾病在这项提案中,该公司将推进我们潜在的治疗,
SPY-DYS45 - 55,一种用于Duchenne肌营养不良症(DMD)的CRISPR/Cas9基因编辑平台
与加州大学洛杉矶分校的研究伙伴合作。杜兴是一个毁灭性的肌肉萎缩
由DMD基因的框架外突变引起的无法治愈的疾病。SPY-DYS45 - 55
去除DMD中的突变热点,以恢复所有杜氏突变的一半的阅读框架。
通过产生符合读码框的外显子45 - 55缺失来治疗患者。这种删除与一种非常
人类Becker肌营养不良症患者的轻度表型。基因编辑的系统递送
平台到肌肉是一个重大的挑战。某些血清型重组腺相关病毒
病毒(AAV)对骨骼肌和心脏具有嗜性。然而,免疫
对病毒的应答禁止重复施用AAV。此外,预先存在
某些个体的免疫力(预计高达70%的成年人存在),排除了他们的免疫力。
有资格享受这种待遇。快速通道提案的目标是设计
应对这些挑战的战略。在第一阶段,我们将确定一个最佳
免疫抑制方案,其允许AAV再给药以改善功效,
适用SPY-DYS45 - 55。在第二阶段,我们将评估长期功能性益处,
在我们的新研究中,AAV-SPY-DYS45 - 55单次或多次注射的毒性和脱靶活性
含有突变的人DMD基因的小鼠模型。最终,这些研究将产生
将SPY-DYS45 - 55转化为杜氏肌营养不良患者所需的初始临床前数据
营养不良
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Courtney Young其他文献
Courtney Young的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 49.37万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 49.37万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 49.37万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 49.37万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 49.37万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 49.37万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 49.37万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 49.37万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 49.37万 - 项目类别: